

This promotional symposium is organised & fully funded by Theramex.

For healthcare professionals only.

Links to Prescribing Information and Adverse Event reporting information can be found below

Targeting bone formation: clinical insights with abaloparatide ▼

53rd European Calcified Tissue Society (ECTS) Congress

Girona Congress Centre, Girona, Spain

Saturday 25th April 2026 (13:30 – 14:30 CET)

Symposium Agenda:

Time	Session title	Presenter
13:30-13:40	Anabolic therapy in osteoporosis: when bone quality matters	Prof Xavier Nogués <i>Hospital del mar, Spain</i>
13:40-14:00	Cortical bone gains with abaloparatide: clinical experience from practice	Prof Heidi Siggelkow <i>University of Göttingen, Germany</i>
14:00-14:20	Early use of anabolic therapy in osteoporosis management	Prof Richard Keen <i>Royal National Orthopaedic Hospital, UK</i>
14:20-14:25	Abaloparatide in context: mechanism, timing and clinical confidence	Prof Xavier Nogués <i>Hospital del mar, Spain</i>
14:25-14:30	Q&A	Faculty: Moderated by Prof Nogués

Abaloparatide is indicated in the treatment of osteoporosis in postmenopausal women at increased risk of fracture

Licensing and availability may vary country by country. Please refer to your country-specific Summary of Product Characteristics before prescribing and your local regulations in relation to your adverse event reporting.

Adverse events should be reported. Reporting forms and information can be found at <https://yellowcard.mhra.gov.uk> or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to Theramex on medinfo.uk@theramex.com or Tel: +44 (0)333 0096795.

For Spanish Healthcare Professionals: Adverse events should be reported. Adverse events should be reported to Theramex at Informacionmedica.es@theramex.com or Tel: +34 911 143 487.

Reporting forms can also be found at <https://www.notificaram.es>

Please:

- Click [Here](#) to access ELADYNOS® (abaloparatide) UK Prescribing Information
- Click [Here](#) to access ELADYNOS® (abaloparatide) EMA Summary of Product Characteristics
- Click [Here](#) to access ELADYNOS® (abaloparatide) Spain Summary of Product Characteristics